All Cases

6 cases · 6 approved / sustained · 0 denied / dismissed · 0 remanded

Doctor

Healthcare · Syria

WeGreened EB-2 (NIW) approved
Ohio 603 days 2025-10-11
The petitioner proposes to continue advancing patient-centric healthcare and medical research in the United States. Their work focuses on clinical practices and public health strategies, specifically addressing COVID-19 vaccination awareness, artificial intelligence in clinical settings, cardiac electrophysiology, and therapeutic optimization for cancer treatments. The endeavor aims to improve patient outcomes and strengthen U.S. public health systems through evidence-based care.
View Case

Medical Laboratory Technician

Healthcare · Syria

WeGreened EB-2 (NIW) rfe approved
608 days 2025-08-06
The petitioner proposes to continue research in laboratory medicine focusing on the mechanisms of complex medical conditions, including autoimmune and vascular disorders. The work involves investigating specific antibodies and proteins to improve diagnostic accuracy and identify new therapeutic targets. This endeavor aims to reduce misdiagnoses and enable more effective clinical treatments for chronic and rare diseases.
View Case

Chief Executive Officer (CEO)

Artificial Intelligence · Syria

WeGreened EB-2 (NIW) approved
200 days 2025-06-25
The petitioner proposes to lead scientific initiatives building machine learning models that accelerate the drug discovery process, specifically focusing on simulating molecular interactions to design personalized cancer treatments. Her work aims to address bottlenecks in drug development by blending multi-omics data with predictive AI systems to reduce costs and increase precision.
View Case

Others

Pharmaceuticals · Syria

WeGreened EB-2 (NIW) approved
343 days 2025-05-13
The petitioner proposes to develop next-generation controlled-release drug delivery systems (CRDDSs) that release medications at controlled rates to improve efficacy and patient compliance for chronic diseases like diabetes and hypertension. His work involves integrating botanical materials into drug matrices to create low-cost, biocompatible alternatives to synthetic excipients. He plans to collaborate with U.S. pharmaceutical institutions to explore liposomal systems and stimuli-responsive materials for enhanced drug release.
View Case

Lecturer

Pharmaceuticals · Syria

WeGreened EB-2 (NIW) approved
Malaysia 173 days 2023-02-01
The petitioner proposes to develop new oral insulin delivery materials and drug delivery carriers using a one-step reproducible process. This work aims to develop DNA and RNA vaccines to treat cancer and other diseases, specifically focusing on nanoparticle-based systems that preserve insulin through stomach acid.
View Case

Assistant Professor

Pharmaceuticals · Syria

WeGreened EB-2 (NIW) approved
65 days 2022-03-23
The petitioner proposes to continue research in the development of new drug delivery carriers based on nanotechnology using a one-step reproducible process. This work focuses on developing DNA and RNA vaccines and treating diseases such as cancer, Alzheimer's, and diabetes. Additionally, the endeavor includes the development of new pediatric drugs designed to mask unpleasant tastes to ease ingestion for children.
View Case